YDJC Restrains Th1 Cell Differentiation by Blocking SREBP2-Mediated Cholesterol Biosynthesis to Alleviate Mucosal Inflammation in Inflammatory Bowel Disease

Scientists demonstrated that YdjC chitooligosaccharide deacetylase homolog (^YDJC) expression is downregulated in inflamed mucosa, particularly in the CD4+ T cells of inflammatory bowel disease patients, and that Ydjc deficiency promotes CD4+ T cell proliferation and Th1 cell differentiation.